Oncternal Therapeutics Inc

NASDAQ:ONCT   3:59:53 PM EDT
1.99
-0.04 (-1.97%)
Products

Oncternal Therapeutics Announces Agreement With U.S. FDA On Phase 3 Registrational Study Design For Zilovertamab In The Treatment Of Mantle Cell Lymphoma

Published: 01/04/2022 21:25 GMT
Oncternal Therapeutics Inc (ONCT) - Oncternal Therapeutics Announces Agreement With U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma.
Oncternal Therapeutics Inc - Global Registrational Study Zilo-301 is Expected to Be Initiated in Q2 of 2022.
Oncternal Therapeutics - FDA Provided Positive Feedback on Proposed Key Clinical, Regulatory Needs of Co's Development Program for Zilovertamab in Mcl.
Oncternal Therapeutics Inc - Co is Also Planning to Conduct Study Zilo-302 During Initial Four Months of Ibrutinib Monotherapy From Study Zilo-301.
Oncternal Therapeutics Inc - Study Zilo-302 is an Open-label Companion Study of Zilovertamab Plus Ibrutinib for Patients Who Have Progressive Disease.